The status of isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes is a major highlight of the recent WHO classification system [11], with IDH1 now being considered a key reference gene for the classification of GBM tumors. This evidence concerns the gene IDH1 and glioblastoma.